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Drug Matrix cell E1: Local and national systems; Reducing harm
S  Seminal  studies  K  Key studies  R  Reviews  G  Guidance  MORE  Search for more studies
S  Wake up cal l  to tackle “s leeping giant” of hepati tis  C (1993). It was  in the early ’90s  when Roger Holmes and the late Dr Tom Wal ler a lerted Bri ta in to the (unti l
1989) invis ible hepati tis  C epidemic: “It may be wise to let s leeping dogs  l ie, but not s leeping giants ,” warned the authors . Since then Bri ta in, i f not letting the virus
l ie, has  not yet mounted an offens ive which measures  up to the dimensions  of the epidemic.
K  Control l ing hepati tis  C requires  methadone and needle exchange but a lso more (2012). Simulation model  for the UK and other countries  highl ights  the need to
increase the proportion of injectors  engaged in both adequate methadone and needle exchange services , and then to do more such as  extending effective treatment
of hepati tis  C infection. Simi lar message from the Netherlands.
K  Combined high impact treatment/exchange reduces  infection risk in Amsterdam (2007). Only injectors  who benefi ted both from adequate dose methadone
maintenance and high coverage needle exchange were less  l ikely to become infected with HIV or hepati tis  C. Simi lar message from the UK.
K  Low threshold methadone extends l i fe expectancy in Barcelona (2005). On average 21 years  were added to the l ives  of heroin users  entering treatment when
across  the ci ty methadone maintenance was made eas ier to access  and remain in, ra is ing the issue of whether to use resources  to extend access  to programmes
oriented to harm-reduction, or reach fewer patients  but with more comprehensive addiction treatment.
K  Outlet divers i fication helped cut HIV risk in Vancouver (2010). Among the pol icy changes  which seem to have led to a  step down in risk behaviour and HIV
incidence were decentral is ing and divers i fying needle and syringe provis ion to more exchange s i tes  and generic and peer-led services , and separating equipment
supply from col lection of used equipment. For more on the dire s i tuation which prompted these changes, see (p. 3 of the PDF fi le, p. 26 of document) this  Findings
analys is .
K  Finland’s  national  programme reverses  HIV escalation (Finnish National  Publ ic Health Insti tute and Department of Infectious  Disease Epidemiology and
Control , 2008). Steeply ris ing HIV incidence in injectors  reversed in Finland shortly after i t launched a national  health counsel l ing and needle exchange
programme. Emerging chal lenge was how to retain the harm reduction focus  and user-friendly ethos  whi le extending access  by integrating in to mainstream health
services .
K  Fears  ungrounded that exchanges  wi l l  increase injecting-related l i tter (2012). Commiss ioning needle exchange provis ion can face opposition due to fears  that
after use injecting equipment wi l l  be left unsafely dis figuring publ ic areas, but this  US study found that the streets  of San Francisco with i ts  needle exchanges  were
freer of l i tter than those of Miami, where needle exchange is  banned.
R  Divers i fy injecting equipment outlets  and combine with treatment and health care (2013). Extens ive UK review updated in 2013 which underpinned the NICE
guidance below. Supports  a  combination of injecting equipment provis ion from outlets  including mobi le services  and vending machines  to attract di fferent user
groups, methadone maintenance, integrated health care and promotion of treatment entry.
R  WHO review finds  needle and syringes  needed but not enough (WHO, 2004). WHO-commiss ioned experts  conclude needle and syringe provis ion is  necessary but
not sufficient to control  HIV. Also needed are education, substi tute prescribing and community development. Findings  a lso in freely avai lable journal  articles  (1 2).
See also associated pol icy guidance.
G  System should del iver more equipment than injectors  need (NICE, 2014). The UK’s  officia l  health advisory body recommends high coverage needle exchange to
combat HIV and hepati tis  C including services  which attract people who inject image- and performance-enhancing drugs  and can cater hol istical ly for injectors
aged under 18. Recommends commiss ioners  assess  coverage and aim for every injector to have even more steri le injecting equipment than they need for every
injection. Based on review above.
G  Supply of injecting equipment cornerstone of national  anti -HIV strategies  (WHO, 2004). Guidance on national  strategies  based on a WHO-commiss ioned review.
G  Local  area systems to curb drug-related deaths  (Publ ic Health England, 2014). Checkl ist for service commiss ioners  and planners  offering ideas  for improving
performance in reducing deaths  by (among other things) promoting cons istent attention to the issue across  local  services  and ensuring services  col laborate to
safely see patients  through the trans itions  between service types  and phases.
G  Seven key components  of anti -disease strategy for injectors  (European Centre for Disease Prevention and Control  and European Monitoring Centre for Drugs  and
Drug Addiction, 2011). Identi fies  seven key intervention components  which should i f poss ible be combined to achieve maximal  synergistic impact including needle
exchange geared to the local  injectors , addiction and disease treatments , testing for infection, vaccination, and health promotion focused on safer injecting,
sexual  health, disease prevention, testing and treatment.
G  Scottish guidance on running and commiss ioning needle exchanges  (Scottish Government, 2010). Includes  needs assessment, locations, opening hours , s taff
training, injecting equipment provis ion pol icies , and integration with other services .
MORE  This  search retrieves  a l l  relevant analyses .
For subtopics  go to the subject search page and this  Findings  hot topic entry on control l ing the spread of hepati tis  C.
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What is this cell about? As described more fully in the cell A1 bite, about reducing the harms experienced by the user as a result of their
drug use, without necessarily reducing use or seeking to overcome dependence. Common interventions include needle exchanges and
substituting a legally prescribed drug of the same type for the original (and usually illegally obtained) substance, also considered as a
treatment for addiction in row 3. This cell is however not about the content of the intervention (for which see cell A1), but about how
implementation and impact are affected by commissioning, contracting and purchasing decisions across an administrative area – more
the domain of commissioners and national planners than individual services.
Where should I start? When the European Union’s central agencies concerned respectively with addiction and infectious disease join
forces, it’s a fair guess the issue is weighty and their resultant recommendations are not to be taken lightly. Exemplifying that is the joint
report on the prevention and control of infectious diseases among injectors from the Lisbon-based European Monitoring Centre for Drugs
and Drug Addiction and the Stockholm-based European Centre for Disease Prevention and Control. Based on “the most robust evidence
available, expert opinion, and best practice within the EU/EEA”, they identified seven key intervention components which “should be
applied and, if possible, combined to achieve the maximum prevention effect through synergy”. The result is an evidence-based blueprint
for local and national planners and commissioners on what to include in their disease-prevention systems, an antidote to the more
common focus on one of the strands in isolation. The authors stuck tightly to addressing the immediate individual and societal harm
caused by infections, refusing to be drawn in to territory more to do with reducing drug use than reducing resultant harm, basing their
recommendations on client-centred ethical principles for such work developed in the UK.
Highlighted study For the UK it has to be this simulation of what it would take to substantially reduce hepatitis C infection among
injectors within say a decade, though the Netherlands might spotlight similar results not from a simulation study, but from what actually
happened to injectors depending on whether they fully participated in both effective methadone and high coverage needle exchange
programmes. Take a look at the UK results encapsulated by Findings, and you will see that though derived from a ‘what if’ exercise, the
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assumptions on which this was based came from six ‘real world’ UK studies. Each related hepatitis C infection among injectors to their
participation in opiate substitution therapy and/or needle and syringe programmes. The analysts translated this data into infection
estimates dependent on whether patients had spent most of their time in treatment and had been supplied NICE’s ideal of at least
enough injecting equipment to use a fresh set each time. The results imply that needle exchange on its own will not sufficiently control
infection. We need the same injectors to be welcomed in to methadone programmes, even though they still sometimes inject, and to be
treated for any infections they already have, plus the other elements identified by the starting point report. But how convincing is this
extrapolation from the six studies? Bear in mind it depends on an association between infection rates and needle exchange and
substitute prescribing which could have been due to other factors. Conceivably, for example, injectors concerned and stable enough to
stay in treatment and make regular use of exchanges would have found other ways to avoid infection, even if exchanges and treatment
were unavailable. That kind of uncertainty dogs studies which underpin some of the most important policy and practice implications in
this sector. Where these are freely and widely available, it is impractical and unethical to deny injectors needle exchange and methadone
to see how many later become infected with life-threatening diseases, yet this is the securest way to prove their benefits.
Issues to think about
 Is hepatitis C preventable? In cell A1 we saw that interventions like methadone prescribing and needle exchange sufficient to
substantially retard the spread of HIV may have no discernible impact on the much more transmissible hepatitis C virus. Now we ask
whether rapid and widespread transmission of the virus can be prevented at all. In principle, the answer is, “Of course! All injectors have
to do is avoid injecting with potentially contaminated equipment by always using a sterile set or one previously used only by them; they
don’t even have to stop injecting.” The real issue though is whether given current anti-infection interventions, in practice we can ever do
enough to ensure this. In 1993 the UK was warned to pull out the financial stops to reverse an epidemic which had already infected most
injectors: “not to do so will lead to a longer term cost that is considerably greater, both in terms of finance and human suffering.” More
was done and thousands of lives saved, but it was nowhere near enough, meaning that by end of the first decade of the 2000s hepatitis C
was still infecting nearly a quarter of injectors within three years of their starting to inject. But could it really ever have been enough?
To gauge the dimensions of the challenge, take another look at the highlighted study. It warned that further substantial reductions in the
prevalence of hepatitis C are unlikely unless both adequate opiate substitute prescribing programmes and high coverage needle
exchange can be scaled-up to reach not 50% of injectors, but over 80% for at least 20 years, an expansion difficult to achieve and
“unlikely to be sustained or funded by policy makers”. Are there any saving graces on the horizon? One clue comes from the study’s
finding that decreasing the length of injecting careers – which in itself would reduce the number of infections – also augments the impact
of the interventions. Maybe recovery-oriented national polices in Britain will indeed curtail drug use and injecting careers. It has also
recently become apparent that injecting is falling out of favour. Extending treatment for infections will help not just avoid liver disease
but prevent new infections. Current treatments are onerous, unpleasant and expensive, but the great hope is that technical advances in
hepatitis C treatment will soon mean nearly all infected injectors can rapidly and easily be cleared of the virus with a short course of
pills, or even a single depot injection, meaning they can no longer transmit infection. In the longer term, these and other developments
may lead to a vaccine to prevent infection.
Meantime multiple strands acting in concert seem the answer, each making their tasks easier for the others. Methadone reduces the
number of injections, making it more feasible for needle exchanges to supply enough equipment, while exchanges help promote
methadone treatment. Treatment of infection cuts the number of sources of the virus, and exchanges and methadone recruit patients for
treatment of their infections and help keep them stable enough to complete the course.
 Spread methadone programmes thin and wide? Referred to here is a long-standing tension in understandings of methadone
maintenance and allied approaches for heroin addiction, seen as both treatments to help end addiction, and as harm reduction while
dependence is maintained by the legally prescribed drug. The Netherlands separates these two objectives in to two treatment systems;
other countries like the UK amalgamate them in the same clinics and patients. Current UK government thinking and expert opinion in the
recovery era is leaning towards the treatment end. Without abandoning harm reduction, the latest attempt to reconcile these objectives
complained that “the protective benefits [ie, harm reduction] have too often become an end in themselves rather than providing a safe
platform from which users might progress towards further recovery”, even if this furthering “will sometimes lead to people following a
potentially more hazardous path”.
Methadone as a route out of not just illegal drug use, but out of itself – a way to end dependence on any opiate-type drug, legal or illegal
– is relatively untried. Results from what has been tried have not been encouraging, perhaps because the intensity and width of support
needed to safely and stably place someone on their own drug-free legs is rarely provided in what is a relatively cheap treatment option. If
this intensive support cannot widely be provided, it leaves most patients in standard programmes offering some keyworker counselling
and other more ad hoc inputs. There seems a real question over whether this degree of support adds much to methadone itself.
Cut-down methadone programmes consisting of little more than prescribing and enough oversight to maintain safety can cut substance
use as effectively as standard programmes. Such programmes can also treat many more patients than programmes with the counselling
and therapy felt desirable to achieve treatment and recovery objectives, extending harm reduction benefits to a whole population of
opiate users. Rather than a treatment for individuals ready, willing and able to ‘recover’ as now conceived, this makes methadone a
public health intervention. The concern is that patients who could have built new, fulfilling, opioid-free lives, will instead be consigned to
decades of the life-dulling drudgery of daily methadone, never entirely free of their addiction.
We have seen from the highlighted study discussion that engaging a very high proportion of injectors in methadone treatment is an
important strand in an anti-infection strategy. Barcelona provides strong evidence that it can also dramatically cut overdose deaths. From
1994 the city adopted a low threshold, “palliative” care model which today in Britain might be seen as lacking recovery ambitions. This
low-cost model meant the programme could engage a high proportion of local opiate addicts and rescue them from the very early death
characteristic of an overdose-prone population. The authors posed the central dilemma: “We cannot deny that [methadone treatment]
effectiveness improves when used as part of more complex programmes including other interventions; however, these ... substantially
increase the cost of treatment, and their implantation may compete with the idea of a generalization of low-threshold [methadone
treatment]. In such cases, policy makers should assign priorities depending on available funding and the epidemiological situation.”
Where do you stand on this issue? Where do you think today the UK should stand? Spread methadone thin and wide, or deepen it with
recovery-oriented interventions for the fewer patients who want and will benefit from these – and who we can afford to treat?
Close Matrix Bite
Drug Matrix cell E1: Local and national systems; Reducing harm 17/06/14
http://findings.org.uk/count/downloads/download.php?file=Matrix/Drugs/E1.htm&format=open 2 / 3
Last revised 17 June 2014. Fi rst uploaded 01 June 2013
 Comment on this  entry
 Suggest a  new document to add to this  cel l
 Return to/go to Drugs  matrix
 Open Effectiveness  Bank home page and enter e-mai l  address  to be alerted to new studies
Drug Matrix cell E1: Local and national systems; Reducing harm 17/06/14
http://findings.org.uk/count/downloads/download.php?file=Matrix/Drugs/E1.htm&format=open 3 / 3
